|Day Low/High||3.91 / 4.12|
|52 Wk Low/High||3.78 / 10.95|
The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Achillion Pharmaceuticals Inc. saw new options begin trading this week, for the June 2017 expiration.
Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the November 18th expiration.
ePoster presentation to detail study results including SVR12 for eight and six week triplet regimen and eight week doublet regimen
Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the August 26th expiration.
Achillion Pharmaceuticals (ACHN) stock rating was increased this morning to 'market outperform' at JMP as the firm believes the company's factor D program is a 'game changer.'
Here are Thursday's top research calls, including an upgrade for Zions, and downgrades for First Solar, Qualcomm and Red Hat.
Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the August 5th expiration.
Trade-Ideas LLC identified Achillion Pharmaceuticals (ACHN) as a weak on high relative volume candidate
Strong Balance Sheet to Support Planned 2016 Clinical Expansion of Complement Factor D Platform
Company's Proprietary Complement Platform Focuses on Advancing Factor D Inhibitor Drug Candidates That Could Treat Ultra-Rare Diseases Such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Other Complement-Mediated Diseases